不同抗菌药物治疗肝硬化上消化道出血感染患者的有效性与安全性评价  

Evaluation on efficacy and safety of different antimicrobial treatments for gastrointestinal bleeding and infections in patients with cirrhosis

作　　者：石瑞春 杨志伟 杨理华 尹文[2] 

机构地区：[1]吴忠市人民医院消化内科,宁夏吴忠751100 [2]第四军医大学西京医院急救中心,陕西西安710032

出　　处：《中华医院感染学杂志》2015年第24期5642-5644,共3页Chinese Journal of Nosocomiology

基　　金：国家自然科学基金资助项目(81070063)

摘　　要：目的研究不同的抗菌药物治疗肝硬化上消化道出血并感染患者临床疗效以及安全性,为临床治疗提供参考依据。方法选择2010年5月-2013年3月接受治疗的126例肝硬化并发上消化道出血并感染患者为研究对象,将其随机分为A、B、C 3组,每组各42例,A组给予亚胺培南治疗、B组给予头孢他啶治疗、C组给予硫酸依替米星治疗,均以静脉滴注方式给药,比较3组患者疗效率,数据采用SPSS 16.0软件进行统计分析。结果 A、B、C 3组患者的治疗有效率分别为83.3%、85.7%、95.2%,A、B两组患者的治疗有效率比较,差异无统计学意义,A与C、B与C组的治疗有效率比较差异有统计学意义(P<0.05)。结论硫酸依替米星是一种在治疗肝硬化并感染患者中优先选择的抗菌药物。OKIECTIVE To investigate the clinical efficacy and safety of the antimicrobial treatment for gastrointestinal bleeding and infections in patients with cirrhosis so as to provide reference for clinical treatment. METHODS Totally 126 cases of liver cirrhosis complicated by upper gastrointestinal bleeding in May 2010 to Mar. 2013 were enrolled as the research subjects. Patients were randomly divided into groups A, B, and C, 42 patients in each group： Group A received imipenem, group B received ceftazidime, group C received etimicin sulfate, all by intra- venous infusion. The 3 groups were compared for clinical efficacy. The software SPSS 16.0 was used for statistical analysis. RESULTS The treatment efficacy was 83.3%, 85.7%, and 95.2% for groups A, B, and C, respectively. ：The difference in treatment efficacy was not significant between group A and group B, but significant be- tween group A and g.roup C as well as betweengroup B and group C （P〈0.05）. CONCLUSION Etimicin sulfate is a prior antimicrobial choice for treatment oi： gastrointestinal bleeding,in patients with Cirrhosis.

关 键 词：抗菌药物 肝硬化 上消化道出血 医院感染 

分 类 号：R573.2[医药卫生—消化系统]